

strongly disagree. The specification provides ample evidence that establish with a reasonable degree of certainty and expectation that the compounds of the present invention would treat CNS disorders in mammals. Attention is directed to the in vivo experiments testing the anti-convulsant activity of various compounds of the present invention or analogs thereof using mice. All of the various examples that were tested exhibited anti-convulsant activity. Therefore, based upon the results, one skilled in the art would conclude that compounds of the present invention would be useful in treating CNS disorder in mammals. Therefore, the specification fully complies with the enablement requirement of 35 USC §112, first paragraph. The rejection of Claims 1-36 under 35 USC §112, first paragraph is obviated, and withdrawal thereof is respectfully requested.

Applicants have amended the specification to correct obvious errors therein. More specifically, applicants have replaced Page 203 with substituted Page 203, which has the headings for the columns indicated. Each of these headings are easily determined by reference to the specification. In addition, applicants have corrected the formula of the substituent for R₂ on Page 207.

No new matter has been added.

Therefore, in view of the Amendment to the specification and the claims, it is respectfully submitted that the present case is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Mark J. Cohen
Reg. No. 32,211

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530

MJC/bm